Among these, in the PACIFIC trial, an exploratory post-hoc analysis requested by EMA revealed no survival benefit from Durvalumab after chemoradiotherapy for unresectable NSCLC in patients with PD-L1 expression < 1% [98]. Here, CD274 is linked to non-small cell lung carcinoma.